Zimlovisertib (PF-06650833) is a potent and selective IRAK4 inhibitor with IC50 of 0.2 nM.
Zimlovisertib (PF-06650833) has IC50 of 2 nM in the PBMC assay as well as in a human whole blood assay.
Zimlovisertib (PF-06650833) shows excellent kinase selectivity in a panel of 278 kinases.
Zimlovisertib (PF-06650833) significantly inhibits LPS-induced TNFα in a dose dependent manner in rats model (0.3-30 mg/kg).
Zimlovisertib (PF-06650833) has favorable in vitro and in vivo ADME profiles and orally active.
